News
February 12, 2025
Fiona Hattey joined the Exciva team as Head of Clinical Operations. She has over thirty years of experience in operationalizing clinical trials.
​
November 4, 2024
Our lead program, EXV-802 for the treatment of agitation in dementia associated with Alzheimer’s disease, received a Fast Track designation from the US FDA
​
April 1, 2024
Dr Hans Moebius, co-founder of Exciva, re-joined the team as a Chief Medical Officer bringing with him over thirty years of leadership in Neurology and Psychiatry drug development and translational medicine
​
June 1, 2023
Francisco Orellana, a seasoned professional who has worked in the biotech sector for over twenty years, joined Exciva as Chief Financial Officer
​
October 25, 2022
The US PTO granted a patent to Exciva for its invention of innovative composition of matter with various therapeutic uses in neuropsychiatry
​​
October 11, 2022
Exciva successfully completed Phase I study of its proprietary EXV-802 combination of dextromethorphan and a 5-HT2A/2C receptor inverse agonist
​
October 26, 2021
Exciva raises €9 million in Series A round led by Andera Partners (full press release)​​